Cargando…

Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention

BACKGROUND AND AIMS: Unfractionated heparin (UFH) and bivalirudin are widely used as anticoagulants in cardiovascular medicine, including for thrombosis prevention during coronary angiography (CAG) and percutaneous coronary intervention (PCI). Little is known of the effects of UFH and bivalirudin on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Qiaowei, Hu, Jia, Ji, Wenfeng, Wang, Liansheng, Jia, Enzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369018/ https://www.ncbi.nlm.nih.gov/pubmed/34447676 http://dx.doi.org/10.14218/JCTH.2020.00150

Ejemplares similares

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes
por: Farag, Mohamed, et al.
Publicado: (2015)

Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention
por: Centurión, Osmar Antonio
Publicado: (2016)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention
por: Li, Zhi-Zhong, et al.
Publicado: (2018)

Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
por: Kapur, Navin K., et al.
Publicado: (2012)

Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019)

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
por: Chai, Lina, et al.
Publicado: (2023)

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
por: Ramana, Ravi K, et al.
Publicado: (2008)

Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Liu, Xiao-Qiang, et al.
Publicado: (2020)

Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
por: Bavry, Anthony A., et al.
Publicado: (2015)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study
por: Wu, Fan, et al.
Publicado: (2022)

Efficacy and Safety of the Reduced Bivalirudin in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention Stratified by Renal Function (REDUCE BOLUS): A Single-Blind, Stratified Randomized, Non-inferiority Trial
por: Hu, Qiang, et al.
Publicado: (2022)

Safety and Efficacy of Bivalirudin versus Unfractionated Heparin Monotherapy in Patients with CAD and DM Undergoing PCI: A Retrospective Observational Study
por: Li, Jing, et al.
Publicado: (2022)

Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Zhang, Juan, et al.
Publicado: (2017)

Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention
por: Huang, Ji, et al.
Publicado: (2018)

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
por: Silvain, Johanne, et al.
Publicado: (2012)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
por: Nicholson, Tricia, et al.
Publicado: (2001)

A meta‐analysis and cost‐minimization analysis of bivalirudin versus heparin in high‐risk patients for percutaneous coronary intervention
por: Sun, Ke‐Xin, et al.
Publicado: (2021)

Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Xu, Haiyan, et al.
Publicado: (2017)

Safety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Ahmad Hamdi, Abdul Hafeez, et al.
Publicado: (2017)

Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up
por: Wojtasik-Bakalarz, Joanna, et al.
Publicado: (2019)

The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions
por: Dobies, David R, et al.
Publicado: (2014)

Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention
por: Vlastra, Wieneke, et al.
Publicado: (2018)

Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin
por: Kikkert, Wouter J., et al.
Publicado: (2015)

Bivalirudin vs heparin in cardiac-cerebral ischemic and bleeding events among Chinese STEMI patients during percutaneous coronary intervention: a retrospective cohort study
por: Bai, Zhichao, et al.
Publicado: (2023)

Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials
por: Bhogal, Sukhdeep, et al.
Publicado: (2020)

The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article
por: Andreou, Constantinos, et al.
Publicado: (2017)

Impact of Diabetes Mellitus on One-Year Clinical Outcomes in Patients Anticoagulated with Bivalirudin Undergoing Elective Percutaneous Coronary Intervention
por: Li, Yulong, et al.
Publicado: (2022)

Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention: a real-world study
por: Wang, Ping, et al.
Publicado: (2022)

Bivalirudin vs. Heparin on Radial Artery Thrombosis during Transradial Coronary Intervention: An Optical Coherence Tomography Study
por: Liu, Zijing, et al.
Publicado: (2020)

Association between circular RNA expression content and severity of coronary atherosclerosis in human coronary artery
por: Hou, Can, et al.
Publicado: (2020)

Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention
por: Faour, Amir, et al.
Publicado: (2021)

Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study
por: Yu, Xiao-Fan, et al.
Publicado: (2022)

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society
por: Kołtowski, Łukasz, et al.
Publicado: (2019)

The effect of dalteparin versus unfractionated heparin on the levels of troponin I and creatine kinase isoenzyme MB in elective percutaneous coronary intervention: a multicenter study
por: Zhang, Guangming, et al.
Publicado: (2014)

Corrigendum to “Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention” [Indian Heart J. 68 (2) (2016) 213–224]
por: Ali-Hasan-Al-Saegh, Sadeq, et al.
Publicado: (2017)

Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study
por: Hu, Yue-cheng, et al.
Publicado: (2021)

Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI
por: Zhang, Junyi, et al.
Publicado: (2018)

Clinical outcomes of bivalirudin versus heparin in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion
por: Zhang, Xiaochun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c5dpvalf4sd700o9e5821h6i3e